Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05889988 · ClinicalTrials.gov registry record

A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

A clinical trial of Breast Neoplasm, sponsored by Mayo Clinic.

Active
Registry status
36
Enrollment target
20
Study locations

NCT05889988: Active study of Breast Neoplasm, sponsored by Mayo Clinic.

NCT05889988 is a study of Breast Neoplasm that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 36 participants, below the 161-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05889988, a study of Breast Neoplasm, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
36 participants
Enrollment target
20
Study locations

Study Summary

Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.

Conditions Studied

Breast Neoplasm

Study Locations (20)

Minnesota

  • Riverwood Healthcare Center - Aitkin
  • Essentia Health Baxter Clinic - Baxter
  • Essentia Health Saint Joseph's Medical Center - Brainerd
  • Essentia Health - Deer River Clinic - Deer River
  • Essentia Health Saint Mary's - Detroit Lakes Clinic - Detroit Lakes
  • Essentia Health Cancer Center - Duluth
  • Essentia Health Ely Clinic - Ely
  • Essentia Health - Fosston - Fosston
  • Fairview Grand Itasca Clinic & Hospital - Grand Rapids
  • Essentia Health Hibbing Clinic - Hibbing
  • Fairview Range Medical Center - Hibbing
  • Essentia Health - International Falls Clinic - International Falls
  • MMCORC CentraCare Monticello Cancer Center - Monticello
  • Essentia Health Moose Lake - Moose Lake
  • Essentia Health - Park Rapids - Park Rapids
  • Fairview Northland Medical Center - Princeton
  • Mayo Clinic in Rochester - Rochester
  • Essentia Health Sandstone - Sandstone
  • Sanford Health Thief River Falls Clinic - Thief River Falls
  • Essentia Health Virginia Clinic - Virginia

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-06-12
Est. Completion 2027-08

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05889988

The ClinicalTrials.gov registry entry for NCT05889988 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 26 other Breast Neoplasm trials with a reported enrollment target (78% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Neoplasm appearing as the primary indexed condition, and to 0 interventions.

NCT05889988 reports 20 study locations spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05889988 about?

NCT05889988 is a clinical study titled "A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients". Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.

What is the current status of trial NCT05889988?

This trial is currently active not recruiting. The enrollment target is 36 participants. The study started on 2023-06-12. Estimated completion is 2027-08.

What conditions does trial NCT05889988 study?

This clinical trial studies the following conditions: Breast Neoplasm.

Who is sponsoring clinical trial NCT05889988?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05889988 being conducted?

This trial has 20 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Neoplasm

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.